Stromba by NASpharma
Stanozolol is also named Winstrol, Rexogin, Stromba or Winthrop. Stanozolol is a derivative of dihydrotestosterone, chemically altered so that the hormone’s anabolic (tissue-building) properties are greatly amplified and its androgenic activity minimized. Stanozolol is classified as an “anabolic” steroid, and exhibits one of the strongest dissociations of anabolic to androgenic effect among commercially available agents. It also cannot be aromatized into estrogens, so you cannot get gynocomastia. Stanozolol is the second most widely used oral steroid, succeeded in popularity only by
Dianabol (methandrostenolone).lt is favored for its ability to promote muscle growth without water-retention, making it highly valued by dieting bodybuilders and competitive athletes.
Stanozolol was first described in 1959/84 It was developed into a medicine by Winthrop Laboratories in Great Britain. Parent firm (Sterling) filed for u.S. patent on the agent in 1961/85 Stanozolol was officially released to the u.S. prescription drug market in 1962 under the brand name Winstrol. Stanozolol was initially prescribed for a variety of medical purposes, including the induction of appetite and lean tissue gain in cases of weight loss associated with many malignant and non-malignant diseases, thepreservation of bone mass during osteoporosis, the promotion of liner growth in children with growth failure, as an anti-catabolic during prolonged corticosteroid therapy or for post-operative and post-trauma (burns, fractures) patients, and even to treat debility in the elderly. The FDA’s control over the prescription drug market had tightened by the mid-1970’s, and the indicated uses for Winstrol were soon narrowed. During this time the FDA officially supported that Winstrol was “Probably Effective” as an adjunct therapy for treating osteoporosis, and for promoting growth in pituitary-deficient dwarfism. With this position, Winthrop was given more time to sell and OH Stanozolol study the agent. Winthrop was able to continually satisfy the FDA regarding Winstrol’s validity as a therapeutic agent, and it remained in the u.S. throughout the 1980’sand 1990’s, a time when many other anabolic steroids were disappearing from the marketplace. Stanozolol was also showing some promise during this period for improving red blood cell concentrations, combating breast cancer, and (more recently) treating angioedema, a disorder
characterized by the swelling of subdermal tissues, often with hereditary causes. Winthrop went through a number of corporate changes during the 1990’s, including a 1991 merger with Elf Sanofi
to form Sanofi Winthrop. Sanofi Winthrop continued on to sell Winstrol in the u.S. For approximately 10 more years, before finally discontinuing the medication because of “manufacturing issues” (Searle was actually making theproduct for Sanofi at the time, and had reportedly ceased production). In 2003, the rights to Winstrol were officially transferred to Ovation Pharmaceuticals. Winstrol remains an approved drug on the u.S. pharmaceutical market, although is not under active production by Ovation label. All forms of Winstrol are presently unavailable in the U.S., although the Winstrol brand remains available in Spain. Numerous other brands and generic forms of the drug are produced in other countries, in both human and veterinary drug markets.
Stanozolol is widely available in both human and veterinary drug markets. Composition and dosage may vary by country and manufacturer. Stanozolol was originally designed as an oral anabolic steroid, containing 2mg of drug per tablet (Winstrol). Other brands commonly contain 5 mg or 10 mg per tablet. Stanozolol can also be found in injectable preparations. These are most commonly water-based suspensions carrying 50 mg/ml of steroid.